This site is intended for health professionals only

Tocilizumab – a new biologic for rheumatoid arthritis

teaser

Tina Hawkins

Rheumatology Pharmacist, Leeds Teaching Hospital NHS Trust

 

Professor Paul Emery

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

President of European League Against Rheumatism, Arthritis UK Professor of Rhematology, University of Leeds, UK

 

Rheumatoid arthritis (RA) is a long-term, chronic, 

autoimmune condition characterised by inflammation of the synovial joints combined with a number of systemic features resulting from abnormal immune response and secondary inflammation.  Uncontrolled disease may result in significant morbidity and mortality.1 Early intervention with disease modifying anti-rheumatic drugs (DMARDs) is essential to prevent long term joint damage, reduce morbidity and improve the patient






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x